And you are certainly not alone
At present, GLP-1 RAs cannot be considered a treatment option for BN also due to safety concerns as highlighted in Chapter 1, and BN is included here only for conceptual completeness
is convening a meeting of PCAC to consider changing the classification of seven popular peptides, thus allowing them to be compounded and sold by prescription
These are comfort-focused, everyday tactics, not medical treatment
Head-to-head clinical data from the SURMOUNT-5 trial shows tirzepatide (Mounjaro) achieves greater weight loss
The regulatory environment surrounding compounded tirzepatide has shifted dramatically, and those shifts directly affect every patient using the medication from any provider, including Orderly Meds